Gabriel Colceriu, MD
Rheumatology · Scottsdale, AZNPI 1134240146
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Boehringer Ingelheim accounts for 81.9% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2019 at $5,434 and has fallen 87.2% since, to $695 in 2025.
Across 136 payments — averaging $95.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$11K
- Actelion Pharmaceuticals US, Inc.$378
- AbbVie$322
- Merck$251
- AstraZeneca$140
- Grifols USA, LLC$119
- plus $1K from 26 others
What the payments were for
- Consulting fees$7,61059%
- Travel & lodging$2,61020%
- Food & beverage$2,73521%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 20 | $10,611 |
| Actelion Pharmaceuticals US, Inc. | 13 | $378 |
| AbbVie | 14 | $322 |
| Merck | 13 | $251 |
| AstraZeneca | 9 | $140 |
| Grifols USA, LLC | 5 | $119 |
| UCB, Inc. | 4 | $116 |
| United Therapeutics Corporation | 6 | $105 |
| Organon | 4 | $78 |
| Sanofi | 4 | $78 |
| Electromed, Inc. | 8 | $76 |
| Verona Pharma, Inc. | 2 | $65 |
| GSK | 3 | $60 |
| Philips North America LLC | 3 | $59 |
| Regeneron Healthcare Solutions, Inc. | 2 | $51 |
| Gilead | 3 | $48 |
| Viiv Healthcare Company | 3 | $48 |
| CMP Pharma, Inc. | 2 | $43 |
| Mylan Specialty L.p. | 2 | $42 |
| Amgen | 2 | $41 |
| Johnson & Johnson | 2 | $34 |
| Sandoz | 1 | $33 |
| Paratek Pharmaceuticals, Inc. | 2 | $31 |
| Insmed, Inc. | 1 | $20 |
| Radius Health, Inc. | 1 | $20 |
| Baxter Healthcare | 1 | $17 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $17 |
| Viatris Specialty LLC | 1 | $14 |
| Advanced Respiratory, Inc | 1 | $14 |
| Pulmonx Corporation | 1 | $12 |
| Oxford Immunotec USA Inc | 1 | $12 |
| Bio Products Laboratory USA, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$6,255
How this compares
$12,964 in reported general payments places this provider in the 70th percentile of 102 rheumatology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 175 | $1,403,130 |
| Humira(Cf) PenAdalimumab | 68 | $544,589 |
| RinvoqUpadacitinib | 65 | $432,322 |
| HumiraAdalimumab | 29 | $216,210 |
| XeljanzTofacitinib Citrate | 24 | $206,313 |
| Cimzia (2 Pack)Certolizumab Pegol | 18 | $172,828 |
| EnbrelEtanercept | 21 | $156,872 |
| KevzaraSarilumab | 16 | $101,540 |
| Xeljanz XrTofacitinib Citrate | 15 | $84,327 |
| Enbrel MiniEtanercept | 12 | $84,175 |
| Cyltezo(Cf) PenAdalimumab-Adbm | 11 | $84,133 |
| Cosentyx Sensoready PenSecukinumab | 12 | $82,800 |
| OrenciaAbatacept | 13 | $77,794 |
| ProliaDenosumab | 44 | $77,490 |
| OtezlaApremilast | 14 | $66,404 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira, Savella | $322 | $655,618107 claims |
| AmgenEnbrel, Prolia, Otezla, Evenity (2 Syringes) | $41 | $338,57794 claims |
| UCB, Inc.Cimzia (2 Pack) | $116 | $172,82818 claims |
| SanofiKevzara | $78 | $101,54016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 102 rheumatology providers in Arizona.
Other rheumatology in Scottsdale
- Paul HowardScottsdale$124K
- Vivek NagarajaScottsdale$36K
- Ramin SabahiScottsdale$13K
- Hani RashidScottsdale$13K
- Mark FreijatScottsdale$10K
- Lester MertzScottsdale$4K
- Megan SullivanScottsdale$3K
- Fawad AslamScottsdale$3K
- Winford GriffingScottsdale$2K
- Nehad SolomanPhoenix$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.